Tango Therapeutics Inc Stock News

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET.

Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancre...

Venture capital fund Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025.

Tango Therapeutics, Inc. (NASDAQ:TNGX ) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers October 23, 2025 8:30 AM EDT Company Participants Elizabeth Hickin - VP of IR & Corporate Communications Barbara Weber - President, CEO & Director Adam Crystal - President of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald &...

Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital, accounts advised by T. Rowe Price Investment Management, Inc., and a large institutional investor Financing participants include Farallon Capital Management, TCGX, Balyasny Asse...

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company will have three poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, including the first clinical data on the no...

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Wednesday, September 3 at 2:45-3:15 PM ET.

Tango (TNGX) Q2 Revenue Drops 52%